Emerging trends in anticoagulation therapy: a bibliometric analysis of DOACs and endogenous coagulation pathway
Zhe Zhu1, Rong Huang2, Hongli He1
1School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
Abstract:
The emergence of direct oral anticoagulants (DOACs) has revolutionized the landscape of anticoagulation, while emerging targeted inhibitors of endogenous coagulation pathways have introduced novel dimensions to anticoagulant therapy. This study aimed to systematically characterize the evolving research landscape through a comprehensive bibliometric analysis, elucidating historical development, research hotspots, and emerging trends in this field. A total of 1993 relevant publications (1990-2024) was systematically retrieved from the Web of Science Core Collection. The bibliometric tools including CiteSpace and HistCite were employed to perform the analysis of historical characteristics, evolution analysis of active topics, and identification of emerging trends. The number of articles in this field was growing rapidly, with the USA, China, and Canada emerging as predominant contributors. Moreover, four principal investigators demonstrated sustained academic dominance through high publication output: Zhao Jinhua, Lip Gregory Y.H., Weitz Jeffrey I., and Gao Na. Three distinct research frontiers were identified, including clinical application and medication safety of DOACs, therapeutic potential of factor XI inhibitors for thrombosis prevention with reduced bleeding risks, and the exploration of fucosylated chondroitin sulfate as a novel iXase-targeting anticoagulant. This study presents a systematic review of DOACs and inhibitors targeting endogenous coagulation pathways in antithrombotic therapy. By identifying current research priorities and emerging trends, this analysis serves as an invaluable resource to guide scholars in recognizing novel therapeutic targets and advancing the development of next-generation anticoagulant drugs.
Insights
Direct oral anticoagulants (DOACs) and novel pathway inhibitors are transforming anticoagulation. This bibliometric analysis maps research trends, identifying key areas like DOAC safety and new antithrombotic targets.
Area of Science:
- Pharmacology and Thrombosis Research
- Bibliometrics and Scientific Trend Analysis
Background:
- Direct oral anticoagulants (DOACs) have significantly advanced anticoagulation therapy.
- Emerging targeted inhibitors of endogenous coagulation pathways offer new therapeutic dimensions.
Purpose of the Study:
- To systematically characterize the evolving research landscape of anticoagulation therapies.
- To elucidate historical development, research hotspots, and emerging trends in DOACs and novel pathway inhibitors.
- To identify key contributors and dominant research frontiers in antithrombotic drug development.
Main Methods:
- Comprehensive bibliometric analysis of 1993 publications (1990-2024) from the Web of Science Core Collection.
- Utilized CiteSpace and HistCite for analyzing historical characteristics, topic evolution, and emerging trends.
- Identified leading countries (USA, China, Canada) and principal investigators in the field.
Main Results:
- Rapid growth in publications, with USA, China, and Canada as leading contributors.
- Four principal investigators (Zhao Jinhua, Lip Gregory Y.H., Weitz Jeffrey I., Gao Na) showed high publication output.
- Three distinct research frontiers identified: DOAC clinical application/safety, Factor XI inhibitors for thrombosis prevention, and iXase-targeting anticoagulants.
Conclusions:
- The study provides a systematic overview of DOACs and endogenous pathway inhibitors in antithrombotic therapy.
- Identified current research priorities and emerging trends to guide future anticoagulant drug development.
- Highlights novel therapeutic targets for next-generation anticoagulant drugs.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.